Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease.

Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC, Forbes A.

Gut. 2006 Mar;55(3):348-55. Epub 2005 Sep 14.

2.

Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.

Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, Kamm MA, Sanderson JD, Knight SC, Forbes A, Stagg AJ, Whelan K, Lindsay JO.

Gut. 2011 Jul;60(7):923-9. doi: 10.1136/gut.2010.232025. Epub 2011 Jan 24.

PMID:
21262918
3.

Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease.

Ng SC, Benjamin JL, McCarthy NE, Hedin CR, Koutsoumpas A, Plamondon S, Price CL, Hart AL, Kamm MA, Forbes A, Knight SC, Lindsay JO, Whelan K, Stagg AJ.

Inflamm Bowel Dis. 2011 Oct;17(10):2027-37. doi: 10.1002/ibd.21590. Epub 2010 Dec 22.

PMID:
21910165
4.

Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats.

Koleva PT, Valcheva RS, Sun X, Gänzle MG, Dieleman LA.

Br J Nutr. 2012 Nov 14;108(9):1633-43. doi: 10.1017/S0007114511007203. Epub 2012 Jan 16.

PMID:
22243836
5.

Fructo-oligosaccharides and fibre in enteral nutrition has a beneficial influence on microbiota and gastrointestinal quality of life.

Wierdsma NJ, van Bodegraven AA, Uitdehaag BM, Arjaans W, Savelkoul PH, Kruizenga HM, van Bokhorst-de van der Schueren MA.

Scand J Gastroenterol. 2009;44(7):804-12. doi: 10.1080/00365520902839675.

PMID:
19347770
6.

Faecal microbiota and short-chain fatty acids in patients receiving enteral nutrition with standard or fructo-oligosaccharides and fibre-enriched formulas.

Majid HA, Emery PW, Whelan K.

J Hum Nutr Diet. 2011 Jun;24(3):260-8. doi: 10.1111/j.1365-277X.2011.01154.x. Epub 2011 Mar 18.

PMID:
21414042
7.

Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease.

Steed H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S.

Aliment Pharmacol Ther. 2010 Oct;32(7):872-83. doi: 10.1111/j.1365-2036.2010.04417.x.

8.

Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells.

Mannon PJ, Leon F, Fuss IJ, Walter BA, Begnami M, Quezado M, Yang Z, Yi C, Groden C, Friend J, Hornung RL, Brown M, Gurprasad S, Kelsall B, Strober W.

Clin Exp Immunol. 2009 Mar;155(3):447-56. doi: 10.1111/j.1365-2249.2008.03799.x. Epub 2008 Dec 15.

9.

CD83+CCR7- dendritic cells accumulate in the subepithelial dome and internalize translocated Escherichia coli HB101 in the Peyer's patches of ileal Crohn's disease.

Salim SY, Silva MA, Keita AV, Larsson M, Andersson P, Magnusson KE, Perdue MH, Söderholm JD.

Am J Pathol. 2009 Jan;174(1):82-90. doi: 10.2353/ajpath.2009.080273. Epub 2008 Dec 18.

10.
11.

Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.

Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO, Dahlerup JF.

Eur J Gastroenterol Hepatol. 2004 Jul;16(7):649-55.

PMID:
15201577
12.

Comparison of bacterial quantities in left and right colon biopsies and faeces.

Lyra A, Forssten S, Rolny P, Wettergren Y, Lahtinen SJ, Salli K, Cedgård L, Odin E, Gustavsson B, Ouwehand AC.

World J Gastroenterol. 2012 Aug 28;18(32):4404-11. doi: 10.3748/wjg.v18.i32.4404.

13.

Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.

Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, Levine AD, Blumberg RS, Fiocchi C.

Gut. 2007 Dec;56(12):1696-705. Epub 2007 Aug 6.

14.

Cytokine gene expression in intestinal tuberculosis and Crohn's disease.

Pugazhendhi S, Jayakanthan K, Pulimood AB, Ramakrishna BS.

Int J Tuberc Lung Dis. 2013 May;17(5):662-8. doi: 10.5588/ijtld.12.0600.

PMID:
23575333
15.

Role of intestinal Bifidobacterium pseudolongum in dietary fructo-oligosaccharide inhibition of 2,4-dinitrofluorobenzene-induced contact hypersensitivity in mice.

Sasajima N, Ogasawara T, Takemura N, Fujiwara R, Watanabe J, Sonoyama K.

Br J Nutr. 2010 Feb;103(4):539-48. doi: 10.1017/S0007114509992145. Epub 2009 Dec 10.

PMID:
20003567
16.

Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease.

van Heel DA, Ghosh S, Hunt KA, Mathew CG, Forbes A, Jewell DP, Playford RJ.

Gut. 2005 Nov;54(11):1553-7. Epub 2005 May 31.

17.

Dietary effects on bifidobacteria and Clostridium perfringens in the canine intestinal tract.

Zentek J, Marquart B, Pietrzak T, Ballèvre O, Rochat F.

J Anim Physiol Anim Nutr (Berl). 2003 Dec;87(11-12):397-407.

PMID:
14633049
18.

CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.

Vuckovic S, Florin TH, Khalil D, Zhang MF, Patel K, Hamilton I, Hart DN.

Am J Gastroenterol. 2001 Oct;96(10):2946-56.

PMID:
11693331
19.

Tumour necrosis factor-alpha production stimulated by heat shock protein 70 and its inhibition in circulating dendritic cells and cells eluted from mucosal tissues in Crohn's disease.

Whittall T, Wang Y, Kelly CG, Thompson R, Sanderson J, Lomer M, Soon SY, Bergmeier LA, Singh M, Lehner T.

Clin Exp Immunol. 2006 Mar;143(3):550-9.

20.

Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-α treatment in patients with Crohn's disease.

Dige A, Magnusson MK, Öhman L, Hvas CL, Kelsen J, Wick MJ, Agnholt J.

Scand J Gastroenterol. 2016;51(6):692-9. doi: 10.3109/00365521.2015.1134649. Epub 2016 Jan 19.

PMID:
26784676

Supplemental Content

Support Center